BCAB - NASDAQ

BioAtla, Inc.

BCAB·NASDAQ

$0.89

+8.2%

HealthcareBiotechnology

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$52.38M

EPS-1.4400

P/E Ratio-0.62

Earnings Date03/26/2026

52.42M

Assets

-56%

3Y-79.0%

5Y+462.0%

10Y+215.0%

38.16M

Total Liabilities

-22%

3Y-12.0%

5Y-42.0%

10Y-15.0%

14.27M

Total Equity

-80%

3Y-93.0%

5Y-125.0%

10Y-150.0%

BioAtla, Inc. Funding & Solvency Profile

BCAB · NASDAQ

Current Assets

Cash & Cash Equivalents49.05M

Net Receivables0.00

Inventory0.00

Other Current Assets447.00K

Total Current Assets51 M

Non-Current Assets

Property, Plant & Equipment1.19M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets1 M

Total Assets

52.42M

Financial Health Analysis

Current Ratio

3.52x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

2.67x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

37 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

98% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

BioAtla, Inc. Balance Sheet

BCAB • NASDAQ

BioAtla, Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	49M	111.5M	215.5M	245M	238.6M	3.7M	10.9M
Cash & Short-Term Investments	49M	111.5M	215.5M	245M	238.6M	3.7M	10.9M
Prepaids	1.7M	4.6M	4.4M	502K	2M	589K	1.5M
Other Current Assets	447K	320K	539K	1.8M	72K	214K	281K
Total Current Assets	51.2M	116.4M	220.4M	247.3M	240.7M	4.5M	12.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.2M	3.1M	5.2M	7M	4.1M	4.7M	3.9M
Other Non-Current Assets	0.0	154K	154K	154K	154K	154K	97K
Total Non-Current Assets	1.2M	3.3M	5.3M	7.1M	4.3M	4.8M	4M
Total Assets	52.4M	119.7M	225.7M	254.4M	244.9M	9.3M	16.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.9M	3.8M	4.2M	1.2M	2.5M	5.1M	2M
Accounts Payable	1.9M	3.8M	4.2M	1.2M	2.5M	5.1M	2M
Accrued Expenses	0.0	3.8M	3.5M	17.2M	6.8M	2.3M	1.9M
Short Term Debt	0.0	0.0	0.0	0.0	0.0	9.7M	0.0
Capital Lease Obligations (Current)	836K	1.6M	1.5M	1.4M	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	19.8M	1.4M	169K
Other Current Liabilities	11.8M	19.1M	13.9M	0.0	3.2M	8.2M	5.2M
Total Current Liabilities	14.5M	28.3M	23.1M	19.8M	32.3M	26.7M	9.2M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	682K	8.4M	15M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	18.8M	309K
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	2.8M	4.6M
Other Non-Current Liabilities	23.6M	19.8M	19.8M	19.8M	2M	8.6M	16M
Total Non-Current Liabilities	23.6M	20.6M	22.3M	23.8M	2.7M	38.6M	35.9M
Capital Lease Obligations	836K	2.5M	4M	5.4M	0.0	0.0	0.0
Total Liabilities	38.2M	49M	45.4M	43.6M	35M	65.3M	45.1M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	89.3M	89.3M
Common Stock	6K	5K	5K	4K	3K	750K	750K
Additional Paid-In Capital	500.3M	486.9M	473.1M	397.1M	300.9M	2.3M	0.0
Retained Earnings	-486M	-416.3M	-292.8M	-186.3M	-90.9M	-148.4M	-118.6M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	-1.4M
Total Stockholders' Equity	14.3M	70.7M	180.3M	210.8M	210M	-56M	-28.5M
Total Equity	14.3M	70.7M	180.3M	210.8M	210M	-56M	-28.4M
Minority Interest	0.0	0.0	0.0	0.0	0.0	-47K	19K
SUMMARY
Total Liabilities & Equity	52.4M	119.7M	225.7M	254.4M	244.9M	9.3M	16.6M
Total Debt	836K	2.5M	4M	5.4M	682K	18.1M	15M
Net Debt	-48.2M	-109M	-211.5M	-239.6M	-237.9M	14.4M	4.1M
Shares Outstanding	58,792,088	58,792,088	58,792,088	58,792,088	58,792,088	58,792,088	58,792,088

SEC Filings

BCAB - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2025 N/A	November 21, 2025	November 20, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 13, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 22, 2025	September 16, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 07, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 07, 2025	August 07, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 20, 2025	June 17, 2025	2025	View Filing
8-K 8-K 2025 N/A	May 16, 2025	May 12, 2025	2025	View Filing
S-3 S-3 N/A	May 06, 2025	May 06, 2025		View Filing
10-Q 10-Q 2025 Q1 Q1	May 06, 2025	March 31, 2025	2025	View Filing

Showing 1 to 10 of 83 filings

Related Guides

Blog Categories

Continue your BCAB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.